Regentis Biomaterials closed a US $15MM Series D investment round. Funds will primarily support a pivotal U.S. clinical trial of GelrinC® hydrogel, a cell-free implant for the treatment of articular knee cartilage injuries.
The round was led by Haisco Pharmaceutical Group in China, which will serve as exclusive distributor for GelrinC in that region.
Source: Regentis Biomaterials
Implanted as a liquid, GelrinC cures in situ to form a resorbable implant that is gradually replaced by newly regenerated cartilage.
In an earlier trial in Europe and Israel, GelrinC provided patients with sustained functional improvement at two years as well as significant pain reduction. The product received CE Mark approval in early 2013.
In 2012, Regentis Biomaterials raised $10MM in a Series C financing.